Byetta 5 mcg

Exenatide 5 mg.

Dosing & Uses


Dosage Forms & Strengths

injectable solution, prefilled pen

  • 250 mcg/mL (1.2 mL vial)
  • 250 mcg/mL (2.4 mL vial)

Diabetes Mellitus, Type 2

Adjunct to diet and exercise to improve glycemic control with DM type 2; monotherapy or as an adjunct therapy with thiazolidinediones, metformin, or a sulfonylurea; or add-on therapy to insulin glargine (a long-acting insulin), with or without metformin and/or a thiazolidinedione, in patients who are not achieving adequate glycemic control on insulin glargine alone

Immediate-release (Byetta): 5 mcg SC q12hr within 60 minutes prior to meal intially; after 1 month, may increased to 10 mcg q12hr

Switching from immediate-release to extended-release

  • Initiate weekly extended-release SC injections 1 day after discontinuing immediate-release exenatide (Byetta)
  • May experience increased blood glucose levels for approximately 2 weeks after initiating extended-release (Bydureon) therapy
  • May initiate extended-release exenatide without pretreating with the immediate-release dosage form

Dosage Modifications

Renal impairment

  • Mild (CrCl 50-80 mL/min): No dosage adjustment required
  • Moderate (CrCl 30-50 mL/min): Caution when initiating or escalating dose
  • Severe (CrCl <30 mL/min) or ESRD: Not recommended
  • Renal transplantation: Use with caution

Intracranial Hypertension (Orphan)

Orphan designation for idiopathic intracranial hypertension


  • Alan Boyd Consultants Ltd; Electra House, Crewe Business Park; Crewe, UK
Safety and efficacy not established

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Byetta 5 mcg only for the indication prescribed.

Verified References
  • FDA Feb 11, 2018
  • CDC Feb 11, 2018
  • Mayo Clinic Feb 11, 2018
  • accessed Feb 11, 2018
  • Medscape accessed Feb 11, 2018
  • Epocrates accessed Feb 11, 2018
  • Webmd accessed Feb 11, 2018